FMP
Virtus LifeSci Biotech Clinical Trials ETF
BBC
AMEX
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
24.4 USD
0.4064 (1.67%)
Valuation Date:
Dec 20, 2024 3:30 PM
Share Price on Valuation Date
$24.4
Stock Beta
0.95
Shares Outstanding
453315